Infectious Disease Testing Market to Grow with a CAGR of 7.71% through 2030F
Increasing prevalence of emerging diseases and
technological advancement in advanced diagnostic technologies is expected to
drive the Global Infectious Disease Testing Market growth in the forecast
period, 2026-2030.
According to TechSci Research report, “Infectious Disease
Testing Market – Global Industry Size, Share, Trends, Competition Forecast
& Opportunities, 2030F”, the Global Infectious Disease Testing Market
stood at USD 34.09 billion in 2024 and is anticipated to grow with a CAGR of
7.71% in the forecast period. The growth of the global infectious
disease testing market is primarily driven by the increasing prevalence of
infectious diseases such as hepatitis, influenza, and HIV. There is a rising
demand for point-of-care diagnostic tests and increased funding from both
private and government organizations for diagnostic service centers.
Advancements in technologies in the field of infectious disease diagnostics
contribute to this growth.
The global geriatric population is on the rise, with over 727.0 million individuals worldwide falling into the 65 and above age group. Due to factors such as multimorbidity, reduced immune function, and physiological changes associated with aging, the elderly are more vulnerable to COVID-19. In 2021, the CDC reported that 80% of COVID-19-related deaths occurred in individuals over 65 years old. Consequently, continuous testing of this demographic is crucial to prevent severe infections, presenting growth opportunities for molecular diagnostic tests in countries like Russia, Japan, and the U.S., which have the highest elderly populations globally. Given the diverse nature of infectious diseases and the increasing resistance of causative agents, it is imperative that the infectious disease molecular diagnostics test menus remain dynamic and comprehensive.
For example, when the coronavirus outbreak in China was declared a global health emergency by the WHO in January 2020, RT-PCRs and sequencing tools were employed to identify and characterize the virus. An anticipated increase in external funding for conducting clinical studies in infectious disease molecular diagnostics is expected to drive market growth. Funding plays a significant role in the product development process.
Browse over XX market data Figures spread through XX
Pages and an in-depth TOC on "Global Infectious Disease Testing Market”
The Global Infectious Disease Testing Market is segmented
into product & service, technology, disease, end user, regional
distribution, and company.
Based on disease, the segment of the Human Immunodeficiency
Virus (HIV) was projected to hold a significant market share during the forecast
period. The study anticipates substantial growth in this segment. According to
the updated data from the Minority of HIV/AIDS Fund (MHAF), United States
Department of Health and Human Services Statistics in June 2021, there were
approximately 37.6 million people living with HIV worldwide in 2020, including
35.9 million adults and 1.7 million children under the age of 15. The same
source also estimates that around 1.5 million people globally contracted HIV in
2020. The increasing prevalence of HIV and the demand for diagnostic tests and
detection are driving the market expansion.
The Human Rights Campaign (HRC) Foundation and "Us
Helping Us" launched the first in-home HIV testing program for residents
in the United States in August 2021. This initiative, along with other global
efforts, is expected to contribute to market growth during the forecast period,
as it raises awareness about HIV. The market's expansion will be accelerated by
new research and developments, technological advancements, and the introduction
of technologically enhanced products by key competitors. For instance, Altona
Diagnostics One introduced the 1.5 AltoStar HIV RT-PCR Kit in April 2021, an
in-vitro diagnostic test that uses real-time RT-PCR technology to identify and
quantify HIV-specific RNA in human plasma. Therefore, considering the
increasing HIV infections, ongoing research and developments, and technological
advancements, the Human Immunodeficiency Virus (HIV) segment is expected to
experience significant growth over the forecast period.
Based on technology, Molecular diagnostics was the dominant
segment in the global infectious disease testing market, primarily due to its
high accuracy, sensitivity, and ability to detect pathogens at the genetic
level. This method enables early and precise identification of a wide range of
infectious agents, including viruses, bacteria, and fungi, making it invaluable
in clinical decision-making and outbreak management. The demand for molecular
diagnostics surged during the COVID-19 pandemic, as RT-PCR became the gold
standard for virus detection. Beyond COVID-19, molecular techniques are widely
used for diagnosing infections such as HIV, hepatitis, tuberculosis, and HPV.
The adoption of multiplex PCR and real-time PCR technologies has further
strengthened the segment, allowing simultaneous detection of multiple pathogens
from a single sample. Advancements in automation, portability, and the
development of rapid molecular point-of-care tests have expanded their use
beyond centralized laboratories to clinics and remote settings. These
advantages, combined with ongoing innovations in genomics and precision
medicine, ensure molecular diagnostics maintains its leadership in infectious
disease testing.
Based on region, Asia-Pacific is the fastest-growing region
in the global infectious disease testing market due to several key factors. The
region faces a high burden of infectious diseases such as tuberculosis,
hepatitis, dengue, and emerging zoonotic infections, driving demand for early
and accurate diagnostics. Rapid urbanization, dense populations, and variable
hygiene conditions contribute to frequent outbreaks, making effective testing
essential. Governments across Asia-Pacific are increasing healthcare
investments, strengthening disease surveillance programs, and promoting early
diagnosis to combat public health threats. In parallel, rising healthcare
awareness and improving access to medical services, especially in countries
like India, China, and Southeast Asian nations, are expanding the reach of
diagnostic testing. The growing presence of local diagnostic manufacturers,
advancements in molecular and point-of-care technologies, and strategic
partnerships with global healthcare players are accelerating innovation and
affordability. These combined factors position Asia-Pacific as a dynamic and
rapidly expanding market within the global infectious disease diagnostics
landscape.
Major companies operating in Global Infectious
Disease Testing Market are:
· Biomérieux SA
· Abbott Laboratories Inc.
· Becton, Dickinson and Company
· Bio-Rad Laboratories Inc.
· Danaher Corporation
· F. Hoffmann-La Roche AG
· Siemens Healthineers AG
· Thermo Fisher Scientific Inc.
· Quidel Corporation
· Trinity Biotech PLC
Download Free Sample Report
Customers can also request for 10% free customization
on this report.
“The global infectious disease testing market is
experiencing robust growth, driven by factors like the rising prevalence of
infectious pathogens, heightened public health awareness, and the increasing
emphasis on early diagnosis and prevention. Technological innovations such as
molecular diagnostics, rapid point-of-care assays, and multiplex testing are
expanding access to faster, more accurate results. The growth in decentralized
healthcare settings, including remote clinics and home testing, is fueling demand.
Frequent outbreaks ranging from seasonal influenza to emerging diseases like
mpox, have prompted governments and private players to bolster screening
programs and invest in diagnostic infrastructure. However, the innovations,
expanded testing coverage, and proactive health initiatives are propelling
sustained market expansion”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.
“Infectious Disease Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product & Service (Assays, Kits, & Reagents, Instruments, Services & Software), By Technology (Molecular Diagnostics, Immunoassay, Microbiology, Others), By Disease (Hepatitis, Human Papillomavirus (HPV), Human Immunodeficiency Virus (HIV), Tuberculosis (TB), Hospital-Acquired Infections (HAIs), Others), By End User (Hospital and Clinical Laboratories, Diagnostic Reference Laboratories, Academic/Research Institutes, Others), By Region and Competition, 2020-2030F”, has
evaluated the future growth potential of Global Infectious Disease Testing
Market and provides statistics & information on market size, structure and
future market growth. The report intends to provide cutting-edge market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Infectious Disease
Testing Market.
Contact
TechSci Research LLC
420 Lexington Avenue
Suite 300, New York
United States- 10170
M: +13322586602
Email: [email protected]
Web: https://www.techsciresearch.com